e faecalis v583 (ATCC)
99
Structured Review
ATCC
e faecalis v583

E Faecalis V583, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 741 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fluorescence+microscope+data/Enterococcus+faecalis/pmc06833023-50-1-4
Average 99 stars, based on 741 article reviews

E Faecalis V583, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 741 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fluorescence+microscope+data/Enterococcus+faecalis/pmc06833023-50-1-4
Average 99 stars, based on 741 article reviews
e faecalis v583 - by Bioz Stars,
2026-11
99/100 stars
Images
1) Product Images from "Eradication of Vancomycin-Resistant Enterococci by Combining Phage and Vancomycin"
Article Title: Eradication of Vancomycin-Resistant Enterococci by Combining Phage and Vancomycin
Journal: Viruses
doi: 10.3390/v11100954
Figure Legend Snippet: Bacterial strains and their sensitivities to phage EFLK1, vancomycin and combined treatment.
Techniques Used: Isolation
Figure Legend Snippet: Representative depiction of vancomycin minimal inhibitory concentration (MIC) for E. faecalis V583 (VRE) by serial dilutions. The results are mean ± SD based on three independent biological replicates.
Techniques Used: Concentration Assay
Figure Legend Snippet: Treatment of planktonic bacteria with 1.2 × 10 8 plaque forming units (PFU)/well phage EFLK1 (anti- E. faecalis phage) combined with 0.015 mg/mL vancomycin reduced VRE growth. Total growth was inhibited in the combination of 0.015 mg vancomycin/mL and 1.2 × 10 8 PFU/well phage EFLK1 (red). VRE control depicts untreated bacteria showing maximal growth (blue). A longer lag phase was observed after treatment with 0.015 mg/mL vancomycin (green) or phage EFLK1 (1.2 × 10 8 PFU/well) alone (purple). The combined treatment reduced the bacterial maximum optical density (OD) with better effect than that of the phages or vancomycin alone. The results are mean ± SD based on 3 independent biological replicates.
Techniques Used: Bacteria, Control
Figure Legend Snippet: Viable counts of planktonic vancomycin-resistant E. faecalis following a combined treatment of phage EFLK1 and vancomycin. The colony forming units (CFU)/mL of VRE treated with 0.015 mg/mL vancomycin combined with phage EFLK1 1.2 × 10 8 PFU/well is presented. Bacteria were below the limit of detection after treating the cells by combining phage EFLK1 and vancomycin. Bacteria treated only with vancomycin showed survival scores like those of the untreated bacteria; cells treated with phage EFLK1 showed medium survival rates. Combining vancomycin and phage EFLK1 caused seven log reductions in CFU/mL. Light gray = vancomycin-treated bacteria, dark gray = phage EFLK1 treatment, black = phage EFLK1 + vancomycin. Statistically significant ( p < 0.01) compared to the untreated control. The results are mean ± SD based on three independent biological replicates.
Techniques Used: Bacteria, Control
Figure Legend Snippet: E. faecalis biofilm biomass following treatment with phage EFLK1 (1.2 × 10 8 PFU/well) and vancomycin (0.015 mg/mL). Treatment with combinations of phage EFLK1 and vancomycin significantly decreased bacterial biomass (87% reduction) as evaluated by crystal violet staining. The results are presented as percentages, normalized to the biofilm biomass controls. Light gray = vancomycin-treated bacteria, dark gray = phage EFLK1 treatment served as the control, black = phage EFLK1 + vancomycin treatment. Statistically significant ( p < 0.05) compared to the untreated control. The results are mean ± SD based on three independent biological replicates.
Techniques Used: Staining, Bacteria, Control
Figure Legend Snippet: Combinations of phage EFLK1 and vancomycin target VRE. Scanning electron microscopy images (MAG: A – C : 20,000, D : 2000): ( A ) E. faecalis 72-h biofilm. ( B ) Biofilm exposed to vancomycin alone, showing no effect. ( C ) E. faecalis biofilm exposed to phage EFLK1 showing bacterial lysis, leaving mainly the extracellular matrix. ( D ) E. faecalis biofilm exposed to vancomycin and phage EFLK1 showing massive bacterial lysis, degradation and biofilm deformation, leaving almost no trace of biofilm.
Techniques Used: Electron Microscopy, Lysis
Figure Legend Snippet: Alexa Fluor 647 wheat germ agglutinin (WGA) stains EFLK1 survivors . Confocal microscopy images (MAG: 60): ( A – B ) vancomycin resistant E. faecalis V583 show low fluorescence level, indicating no conjugation to N -acetylglucosamine. ( C – D ) EFLK1 survivors show high fluorescence levels followed the conjugation of Alexa Fluor 647 WGA to N -acetylglucosamine.
Techniques Used: Confocal Microscopy, Fluorescence, Conjugation Assay
Figure Legend Snippet: Fluorescence activated cell sorting (FACS) analysis: higher fluorescence levels are obtained followed phage treatment. Red = EFLK1 survivors, black = untreated control of E. faecalis V583. Statistically significant ( p < 0.01) compared to the untreated control. The results are mean ± SD based on six independent biological replicates.
Techniques Used: Fluorescence, FACS, Control
Related Articles
Control:Article Title: [2601.22382] Purely Agentic Black-Box Optimization for Biological Design Article Snippet: .. The bacterial panel utilized in this study consisted of the following pathogenic strains: Acinetobacter baumannii ATCC 19606; A. baumannii ATCC BAA-1605 (resistant to ceftazidime, gentamicin, ticarcillin, piperacillin, aztreonam, cefepime, ciprofloxacin, imipenem, and meropenem); Escherichia coli ATCC 11775; E. coli AIC221 [MG1655 phnE 2::FRT, polymyxin-sensitive control]; E. coli AIC222 [MG1655 pmrA53 phnE 2::FRT, polymyxin-resistant]; E. coli ATCC BAA-3170 (resistant to colistin and polymyxin B); E. coli K-12 BW25113; Enterobacter cloacae ATCC 13047; Klebsiella pneumoniae ATCC 13883; K. pneumoniae ATCC BAA-2342 (resistant to ertapenem and imipenem); Pseudomonas aeruginosa PAO1; P. aeruginosa PA14; P. aeruginosa ATCC BAA-3197 (resistant to fluoroquinolones, β-lactams, and carbapenems); Salmonella enterica ATCC 9150; S. enterica subsp. enterica Typhimurium ATCC 700720; Bacillus subtilis ATCC 23857; Staphylococcus aureus ATCC 12600; S. aureus ATCC BAA-1556 (methicillin-resistant); Article Title: A deep reinforcement learning platform for antibiotic discovery Article Snippet: .. The pathogenic strains utilized included Acinetobacter baumannii ATCC 19606, Acinetobacter baumannii ATCC BAA-1605 (resistant to ceftazidime, gentamicin, ticarcillin, piperacillin, aztreonam, cefepime, ciprofloxacin, imipenem, and meropenem), Escherichia coli ATCC 11775, Escherichia coli AIC221 [MG1655 phnE_2::FRT, polymyxin-sensitive control], E. coli AIC222 [MG1655 pmrA53 phnE_2::FRT, polymyxin-resistant], Escherichia coli ATCC BAA-3170 (resistant to colistin and polymyxin B), Enterobacter cloacae ATCC 13047, Klebsiella pneumoniae ATCC 13883, Klebsiella pneumoniae ATCC BAA-2342 (resistant to ertapenem and imipenem), Pseudomonas aeruginosa PAO1, Pseudomonas aeruginosa PA14, Pseudomonas aeruginosa ATCC BAA-3197 (resistant to fluoroquinolones, beta-lactams, and carbapenems), Salmonella enterica ATCC 9150, Salmonella enterica subsp. enterica Typhimurium ATCC 700720, Bacillus subtilis ATCC 23857, Staphylococcus aureus ATCC 12600, Staphylococcus aureus ATCC BAA-1556 (resistant to methicillin), Article Title: Designing AI-programmable therapeutics with the EDEN family of foundation models Article Snippet: .. The bacterial panel utilized in this study consisted of the following pathogenic strains: Acinetobacter baumannii ATCC 19606; A. baumannii ATCC BAA-1605 (resistant to ceftazidime, gentamicin, ticarcillin, piperacillin, aztreonam, cefepime, ciprofloxacin, imipenem, and meropenem); Escherichia coli ATCC 11775; E. coli AIC221 [MG1655 phnE_2::FRT, polymyxin-sensitive control]; E. coli AIC222 [MG1655 pmrA53 phnE_2::FRT, polymyxin-resistant]; E. coli ATCC BAA-3170 (resistant to colistin and polymyxin B); E. coli K-12 BW25113; Enterobacter cloacae ATCC 13047; Klebsiella pneumoniae ATCC 13883; K. pneumoniae ATCC BAA-2342 (resistant to ertapenem and imipenem); Pseudomonas aeruginosa PAO1; P. aeruginosa PA14; P. aeruginosa ATCC BAA-3197 (resistant to fluoroquinolones, β-lactams, and carbapenems); Salmonella enterica ATCC 9150; S. enterica subsp. enterica Typhimurium ATCC 700720; Bacillus subtilis ATCC 23857; Staphylococcus aureus ATCC 12600; S. aureus ATCC BAA-1556 (methicillin-resistant); Article Title: Enterococcus-derived cytolysin exacerbates ischemic stroke by disrupting the blood-brain barrier via NLRP3 activation. Article Snippet: .. To investigate the effects of cytolysin in vivo, mice were orally gavaged once daily for 14 consecutive days with 5 × 108 colony-forming units (CFU) of either a Article Title: [2510.01988] PepCompass: Navigating peptide embedding spaces using Riemannian Geometry Article Snippet: .. J.2 Bacterial Strains and Growth Conditions The bacterial panel utilized in this study consisted of the following pathogenic strains: Acinetobacter baumannii ATCC 19606; A. baumannii ATCC BAA-1605 (resistant to ceftazidime, gentamicin, ticarcillin, piperacillin, aztreonam, cefepime, ciprofloxacin, imipenem, and meropenem); Escherichia coli ATCC 11775; E. coli AIC221 [MG1655 phnE_2::FRT, polymyxin-sensitive control]; E. coli AIC222 [MG1655 pmrA53 phnE_2::FRT, polymyxin-resistant]; E. coli ATCC BAA-3170 (resistant to colistin and polymyxin B); Enterobacter cloacae ATCC 13047; Klebsiella pneumoniae ATCC 13883; K. pneumoniae ATCC BAA-2342 (resistant to ertapenem and imipenem); Pseudomonas aeruginosa PAO1; P. aeruginosa PA14; P. aeruginosa ATCC BAA-3197 (resistant to fluoroquinolones, β-lactams, and carbapenems); Salmonella enterica ATCC 9150; S. enterica subsp. enterica Typhimurium ATCC 700720; Bacillus subtilis ATCC 23857; Staphylococcus aureus ATCC 12600; S. aureus ATCC BAA-1556 (methicillin-resistant); Bacteria:Article Title: PepGlider: Property Regularized VAE for interpretable and controllable peptide design Article Snippet: .. The dataset includes measurements against Gram-negative bacteria ( Acinetobacter baumannii ( A. baumannii ) ATCC 19606, E. coli ATCC 11775, E. coli AIC221, carbapenem-resistant E. coli AIC222, Klebsiella pneumoniae ( K. pneumoniae ) ATCC 13883, Pseudomonas aeruginosa ( P. aeruginosa ) PAO1 and PA14) and Gram-positive bacteria ( S. aureus ATCC 12600, MRSA ATCC BAA-1556, vancomycin-resistant Enterococcus faecalis ( E. faecalis ) Isolation:Article Title: Electrospun Phage-Loaded Bilayer Nanofibrous Scaffolds for Wound Dressing Applications: A Comparative Study of Different Bacteriophages Article Snippet: .. In Vivo:Article Title: Enterococcus-derived cytolysin exacerbates ischemic stroke by disrupting the blood-brain barrier via NLRP3 activation. Article Snippet: .. To investigate the effects of cytolysin in vivo, mice were orally gavaged once daily for 14 consecutive days with 5 × 108 colony-forming units (CFU) of either a other:Article Title: Antimicrobial and Antibiofilm Activities of Some Antioxidant 3,4-Dihydroxyphenyl-Thiazole-Coumarin Hybrid Compounds: In Silico and In Vitro Evaluation Article Snippet: Q839Z1 , reviewed , |